MedTrace Logo

A Study of AB-106 in Chinese Healthy Adult Men Evaluated the Effects of Itraconazole and Rifampicin on AB-106 PK

NCT05357820 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 56

Last updated 2024-11-21

No results posted yet for this study

Summary

AB-106-C110 is China-only study, for investigating the drug interaction between AB-106 and CYP3A4 inhibitor (Itraconazole)/CYP3A4 inducer (Rifampin)（n=56）

Conditions

Interventions

DRUG

AB-106, Itraconazole

single dose AB-106 at Day1, Itraconazole QD at Day14\~Day28, single dose AB-106 at Day17

DRUG

AB-106, Rifampicin

single dose AB-106 at Day1, Itraconazole QD at Day14\~Day32, single dose AB-106 at Day21

Sponsors & Collaborators

  • Nuvation Bio Inc.

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-07-19
Primary Completion
2021-12-03
Completion
2021-12-03

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05357820 on ClinicalTrials.gov